

Anti-CALLA [SS2/36] rAb

Catalogue number: 154808

Sub-type: Primary antibody

Images:

Contributor

Inventor:

Institute: Absolute Antibody; University of Oxford

Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: Anti-CALLA [SS2/36] rAb

Alternate name:

Class: Recombinant

Conjugate: Unconjugated

Description: CALLA is expressed on B- and T- cell precursors, bone marrow stromal cells, lymphoblastic, Burkitt's, and follicular germinal center lymphomas, and on cells from patients with chronic myelocytic leukemia (CML). CALLA is a cell surface enzyme that inactivates a variety of peptides. SS2/36 is a marker for Acute Lymphocytic Leukaemia (ALL). CALLA is widely used for identification of "common" type Acute Lymphocytic Leukaemia (ALL).

Purpose:

Parental cell:

Organism:

Tissue:

Model:

Gender:

Isotype: IgG1

Reactivity: Human

Selectivity:

Host: Mouse

Immunogen: Common acute lymphoblastic leukaemia cells

Immunogen UNIPROT ID:

Sequence:

Growth properties:

Production details:

Formulation:

Recommended controls:

Bacterial resistance:

Selectable markers:

Additional notes:

Target details

Target: Common Acute Lymphocytic Leukaemia Antigen (CALLA, CD10)

Target alternate names:

Target background: CALLA is expressed on B- and T- cell precursors, bone marrow stromal cells, lymphoblastic, Burkitt's, and follicular germinal center lymphomas, and on cells from patients with chronic myelocytic leukemia (CML). CALLA is a cell surface enzyme that inactivates a variety of peptides. SS2/36 is a marker for Acute Lymphocytic Leukaemia (ALL). CALLA is widely used for identification of "common" type Acute Lymphocytic Leukaemia (ALL).

Molecular weight:

Ic50:

Applications

Application: FACS ; IF ; IHC ; IP ; WB

Application notes:

Handling

Format: Liquid

Concentration:

Passage number:

Growth medium:

Temperature:

Atmosphere:

Volume:

Storage medium:

Storage buffer: Unpurified anti-serum from rabbit preserved in 0.02% Thiomersal

Storage conditions:

Shipping conditions: Shipping at 4° C

Related tools

Related tools:

References

References: 4PD Fused Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells. ; CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells. ; Cui et al. 2015. *Cell*. 161(4):750-61. PMID: 25957683. ; Double immunocytochemical labeling of cell and tissue samples with monoclonal anti-bromodeoxyuridine. ; Fn assessment of glioma pathogenesis by in vivo multi-parametric magnetic resonance imaging and in vitro analyses. ; IL-7-Induced Glycerol Transport and TAG Synthesis Promotes Memory CD8⁺ T Cell Longevity. ; Innis et al. 2010. *Am J Physiol Gastrointest Liver Physiol*. 299(6):G1376-85. PMID: 20864654. ; Intratracheal cell transfer demonstrates the profibrotic potential of resident fibroblasts in pulmonary fibrosis. ; Involvement of SDF1a and STAT3 in granulocyte colony-stimulating factor rescues optic ischemia-induced retinal function loss by mobilizing hematopoietic stem cells. ; Kim et al. 2016. *Int J Dev Neurosci*. :. PMID: 27326907. ; Lin et al. 2013. *Invest Ophthalmol Vis Sci*. 54(3):1920-30. PMID: 23439595. ; Magaud et al. 1989. *J Histochem Cytochem*. 37(10):1517-27. PMID: 2476478. ; Maternal obesity leads to increased proliferation and numbers of astrocytes in the developing fetal and neonatal mouse hypothalamus. ; MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway. ; N-Myc and the cyclin-dependent kinase inhibitors p18Ink4c and p27Kip1 coordinately regulate cerebellar development. ; Perinatal lipid nutrition alters early intestinal development and programs the response to experimental colitis in young adult rats. ; Sheikh et al. 2015. *Oncogene*. PMID: 25772242. ; Tsukui et al. 2015. *Am J Pathol*. :. PMID: 26456579. ; Yao et al. 2016. *Sci Rep*. 6:26050. PMID: 27198662. ; Zhao et al. 2015. *Oncogene*. :. PMID: 26657156. ; Zilio et al. 2017. *J Immunol*. :. PMID: 28396317. ; Zindy et al. 2006. *Proc Natl Acad Sci U S A*. 103(31):11579-83. PMID: 16864777. ; Desamero et al. 2019. *Sci Rep*. 9(1):19635. PMID: 31873082. ; Helbling-Leclerc et al. 2019. *Sci Rep*. 9(1):17024. PMID: 31745226. ; Paul et al. 2019. *J Immunother Cancer*. 7(1):208. PMID: 31387637. ; Dick et al. 2019. *Nat Immunol*. 20(5):664. PMID: 30862954. ; Xu et al. 2019. *Sci Adv*. 5(4):eaav4570. PMID: 31032410. ; Jimenez et al. 2019. *Front Immunol*. 10:2183. PMID: 31620123.